文献速递冠心病外科

冠脉搭桥术后新发房颤的抗凝与胺碘酮处方模式及30天结局

Anticoagulation and amiodarone for new atrial fibrillation after coronary artery bypass grafting: Prescription patterns and 30-day outcomes in the United States and Canada.
PubMed 文献 · J Thorac Cardiovasc Surg · 2020-02-19

该回顾性队列研究分析了2011年7月至2018年6月STS成人心脏手术数据库中首次单纯CABG后新发房颤且无严重并发症的166,747例患者,按出院药物分为胺碘酮±抗凝、单用抗凝和两者均无四组。

要点

  • 出院抗凝未降低30天卒中再入院,但大出血再入院风险增加4.30倍。
  • 未抗凝患者中,出院胺碘酮使用与30天卒中率无显著差异。
  • 仅25.7%患者出院时接受抗凝,平均CHA2DS2-VASc评分3.2±1.3。

核心结论

  • CABG术后新发房颤出院抗凝与30天出血增加相关,而卒中无差异。
  • 需前瞻性随机研究以明确安全有效的短期和长期管理策略。

研究设计与样本

  • 回顾性队列研究,分析STS成人心脏手术数据库2011年7月至2018年6月数据。
  • 纳入首次单纯CABG后新发房颤且无严重并发症的患者,共166,747例。
  • 按出院药物分为四组:胺碘酮±抗凝、单用抗凝、两者均无。
  • 观察30天结局。

主要发现

  • 25.7%患者出院时接受抗凝,平均CHA2DS2-VASc评分3.2±1.3。

关键数值与推荐

  • 出院抗凝比例25.7%,平均CHA2DS2-VASc评分3.2±1.3。

临床怎么用

  • CABG术后新发房颤出院抗凝需权衡出血风险,尤其CHA2DS2-VASc评分较高者。
  • 抗凝未显著降低30天卒中再入院,但大出血风险增加,应个体化决策。
  • 未抗凝患者中胺碘酮使用与卒中无显著差异,但需结合节律控制需求。

局限性

  • 回顾性研究设计,存在混杂因素。
  • 仅观察30天结局,缺乏长期数据。
  • 未报告抗凝药物类型、剂量及国际标准化比值等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We sought to elucidate national practice patterns regarding anticoagulation and antiarrhythmic medication use at discharge and examine short-term patient outcomes. METHODS: In this retrospective cohort study, we analyzed the data of patients from the Society of Thoracic Surgeons Adult Cardiac Surgery Database from July 2011 to June 2018 who underwent first-time isolated coronary artery bypass graft surgery (CABG) and developed new post-CABG atrial fibrillation (AF) without significant complications. In total, 166,747 patients met study criteria. We examined 30-day outcomes. RESULTS: In total, 166,747 patients were analyzed and divided into 4 groups based on discharge medications: amiodarone with or without anticoagulation, anticoagulation alone, and neither. Demographic characteristics were similar among the 4 groups. In total, 25.7% of patients were discharged on anticoagulation with an average CHA2DS2-VASc score of 3.2 ± 1.3. Anticoagulation use at discharge was not associated with lower 30-day stroke readmissions (adjusted odds ratio [AOR], 0.87; 95% confidence interval [CI], 0.65-1.16; P = .35). Adjusted 30-day readmissions for major bleeding were significantly more common in anticoagulated patients (AOR, 4.30; 95% CI, 3.69-5.03; P < .0001). Among those discharged off anticoagulation, there was no significant difference in adjusted 30-day stroke rates based on amiodarone use at discharge (AOR, 1.19; 95% CI, 0.85-1.66; P = .31). CONCLUSIONS: Post-CABG anticoagulation for new AF is associated with increased bleeding and no difference in stroke at 30 days. Prospective randomized studies are needed to formalize safe and efficacious short- and long-term management strategies.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Matos JD, McIlvaine S, Grau-Sepulveda M, et al. Anticoagulation and amiodarone for new atrial fibrillation after coronary artery bypass grafting: Prescription patterns and 30-day outcomes in the United States and Canada. J Thorac Cardiovasc Surg. 2020. PMID: 32197901. doi:10.1016/j.jtcvs.2020.01.077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。